Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,746.00
Bid: 4,732.00
Ask: 4,736.00
Change: 70.00 (1.50%)
Spread: 4.00 (0.085%)
Open: 4,676.00
High: 4,857.00
Low: 4,666.00
Prev. Close: 4,676.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic review of PT&IC businesses

5 May 2021 07:00

RNS Number : 5331X
Croda International PLC
05 May 2021
 

Press Release

5 May 2021

 

Strategic review of Performance Technologies & Industrial Chemicals businesses

Croda International Plc ("Croda" or the "Group"), which uses smart science to create high performance ingredients and technologies that improve lives, announces a strategic review of its Performance Technologies and Industrial Chemicals ('PTIC') businesses. The core objective will be to establish what ownership structure best serves this part of Croda's business going forward, to create a stronger platform for its future growth. The review is consistent with Croda's prioritisation of investments in faster-growth life science and consumer markets, which now represent over 80% of the Group's profitability.

PTIC is an excellent, world-leading business, with an impressive financial track record. It delivers industry-leading margins across the cycle through well invested manufacturing, innovation and sales operations, supported by a dedicated and experienced global team. It has a highly attractive portfolio, offering customers innovative, sustainable solutions in advanced technologies, and is focused on fast-growth markets in the circular plastic economy, electric vehicles and other renewable technologies. This strong technology portfolio supports PTIC's leading market positions in automotive, polymer and food packaging applications.

The scope of the strategic review will focus on the businesses and activities within PTIC that do not directly support the Consumer Care and Life Sciences sectors. It will consider whether Croda is the best future owner of all the PTIC businesses within the context of opportunities to deploy more capital and resources within PTIC, as well as in Consumer Care and Life Sciences.

The review will assess whether the full potential of PTIC can best be delivered under Croda, as a stand-alone business, or via a full or partial divestment. It will consider the extent of the mutual dependencies between PTIC and the rest of Croda, the practicality of all options, whilst prioritising the best interests of all stakeholders, including employees, customers and shareholders.

The review is expected to conclude by the end of 2021 and, in the meantime, the Group will continue to deliver an excellent service for its customers.

The strategic review is being launched in the context of ongoing improvement in Group trading year to date, continuing the trend seen in the second half of 2020. Customer demand is strong across all regions and sectors, including PTIC, in some cases driven by a recovery in end-consumer demand, in other areas by customer inventory build ahead of anticipated economic recovery. The Group will announce its Half Year Results to 30 June on 27 July 2021.

Further information

 

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQZLFBFELEBBQ
Date   Source Headline
22nd Mar 202111:54 amRNSDirector/PDMR Shareholding
17th Mar 20214:37 pmRNSDirector/PDMR Shareholding
17th Mar 20214:35 pmRNSDirector/PDMR Shareholding
17th Mar 20214:32 pmRNSDirector/PDMR Shareholding
17th Mar 20214:31 pmRNSDirector/PDMR Shareholding
17th Mar 20214:30 pmRNSDirector/PDMR Shareholding
17th Mar 20214:29 pmRNSDirector/PDMR Shareholding
17th Mar 20214:28 pmRNSDirector/PDMR Shareholding
17th Mar 20214:27 pmRNSDirector/PDMR Shareholding
17th Mar 20214:23 pmRNSDirector/PDMR Shareholding
17th Mar 20214:23 pmRNSDirector/PDMR Shareholding
17th Mar 20214:22 pmRNSDirector/PDMR Shareholding
17th Mar 20214:19 pmRNSDirector/PDMR Shareholding
11th Mar 20213:25 pmRNSDirector/PDMR Shareholding
2nd Mar 20217:02 amRNSCroda acquires Alban Muller
2nd Mar 20217:00 amRNSFinal Results
11th Feb 20213:12 pmRNSDirector/PDMR Shareholding
12th Jan 20215:26 pmRNSDirector/PDMR Shareholding
30th Dec 20205:07 pmRNSDirector/PDMR Shareholding
11th Dec 20203:33 pmRNSDirector/PDMR Shareholding
30th Nov 20208:57 amRNSTotal Voting Rights
24th Nov 202012:52 pmRNSCroda completes acquisition of Iberchem
24th Nov 202010:39 amRNSDirector/PDMR Shareholding
24th Nov 202010:38 amRNSDirector/PDMR Shareholding
18th Nov 20205:30 pmRNSCroda International
18th Nov 20203:54 pmRNSResults of the Placing
18th Nov 20207:01 amRNSRetail Offer via PrimaryBid.com
18th Nov 20207:00 amRNSAcquisition of Iberchem
11th Nov 20204:50 pmRNSDirector/PDMR Shareholding
10th Nov 20201:41 pmRNSCOVID-19 vaccine contract
2nd Nov 20203:35 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:29 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:24 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:21 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSVirtual investor seminar on sustainability
13th Oct 20204:57 pmRNSDirector/PDMR Shareholding
5th Oct 20202:42 pmRNSDirector/PDMR Shareholding
11th Sep 20203:39 pmRNSDirector/PDMR Shareholding
11th Sep 20209:48 amRNSDirector/PDMR Shareholding
13th Aug 20207:00 amRNSCroda completes acquisition of Avanti Polar Lipids
11th Aug 20204:32 pmRNSDirector/PDMR Shareholding
28th Jul 20203:19 pmRNSHolding(s) in Company
24th Jul 20201:09 pmRNSDirector/PDMR Shareholding
24th Jul 20201:08 pmRNSDirector/PDMR Shareholding
23rd Jul 20207:00 amRNSResults for the six months ended 30 June 2020
16th Jul 20209:27 amRNSHolding(s) in Company
13th Jul 20204:29 pmRNSDirector/PDMR Shareholding
6th Jul 20202:00 pmRNSCroda acquisition of Avanti Polar Lipids, Inc
3rd Jul 20204:19 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.